Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain

BACKGROUND: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM),...

Descripción completa

Detalles Bibliográficos
Autores principales: Argüelles-Arias, Federico, Bermejo, Fernando, Borrás-Blasco, Joaquín, Domènech, Eugeni, Sicilia, Beatriz, Huguet, José M., de Arellano, Antonio Ramirez, Valentine, William J., Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092579/
https://www.ncbi.nlm.nih.gov/pubmed/35574429
http://dx.doi.org/10.1177/17562848221086131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092579/
https://www.ncbi.nlm.nih.gov/pubmed/35574429
http://dx.doi.org/10.1177/17562848221086131

Ejemplares similares